Curis Inc (CRIS) Stock Price

CRISStock

$1.49−95.54%52W

Market Cap$3.61M

P/E—

PEG Ratio—

Div yield—

Beta3.38

CRIS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-105.03%

Price vs S&P 500 (4W)-72.61%

VGM Score34.39

Book Value / Share (Quarterly)$6.36

P/TBV (Annual)4.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.41%

Cash Flow / Share (Quarterly)$-14.48

Price vs S&P 500 (YTD)-105.30%

Gross Margin (TTM)99.52%

Net Profit Margin (TTM)-80.29%

EPS (TTM)$-10.99

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-10.99

Revenue Growth (5Y)-2.72%

EPS (Annual)$-11.52

ROI (Annual)-138.81%

Gross Margin (Annual)99.52%

Net Profit Margin (5Y Avg)-387.11%

Cash / Share (Quarterly)$7.50

Revenue Growth QoQ (YoY)-65.98%

ROA (Last FY)-37.97%

Revenue Growth TTM (YoY)-36.95%

EBITD / Share (TTM)$-1.83

ROE (5Y Avg)-114.89%

Operating Margin (TTM)-60.50%

Cash Flow / Share (Annual)$-42.08

P/B Ratio0.29x

P/B Ratio (Quarterly)1.72x

Net Income / Employee (Annual)$-315,900

EV / Revenue (TTM)-1.20x

Net Interest Coverage (TTM)-177.56x

ROA (TTM)-79.47%

EV / EBITDA (TTM)-4.54x

EPS Incl Extra (Annual)$-11.52

Current Ratio (Annual)0.49x

Quick Ratio (Quarterly)1.00x

3-Month Avg Trading Volume0.20M

52-Week Price Return-95.54%

Revenue / Employee (TTM)$294,300

Tangible BV / Share (Quarterly)$69.20

P/S Ratio (Annual)0.39x

Asset Turnover (Annual)0.47x

52-Week High$39.00

Operating Margin (5Y Avg)-371.89%

EPS Excl Extra (Annual)$-11.52

Tangible BV CAGR (5Y)-25.67%

26-Week Price Return-93.10%

Quick Ratio (Annual)0.36x

13-Week Price Return-85.77%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.11x

Enterprise Value$-11.36M

Revenue / Share Growth (5Y)26.32%

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)-10.84%

Revenue / Employee (Annual)$393,500

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-80.29%

Cash / Share (Annual)$7.83

3-Month Return Std Dev205.07%

Gross Margin (5Y Avg)97.81%

Net Income / Employee (TTM)$-881,900

ROE (Last FY)-138.81%

Net Interest Coverage (Annual)-9.23x

EPS Basic Excl Extra (Annual)$-11.52

P/FCF (TTM)18.22x

Receivables Turnover (TTM)5.64x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.99

Receivables Turnover (Annual)5.64x

ROI (TTM)-53.31%

P/S Ratio (TTM)0.39x

Pretax Margin (5Y Avg)-387.11%

Revenue / Share (Annual)$14.35

Tangible BV / Share (Annual)$76.00

Price vs S&P 500 (52W)-114.10%

Year-to-Date Return-92.47%

5-Day Price Return-5.70%

EPS Normalized (Annual)$-11.52

ROA (5Y Avg)-56.91%

Net Profit Margin (Annual)-80.29%

Month-to-Date Return-70.32%

Cash Flow / Share (TTM)$-9.25

EBITD / Share (Annual)$-8.42

Operating Margin (Annual)-60.50%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-81.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.99

P/TBV (Quarterly)1.91x

P/B Ratio (Annual)2.34x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-80.29%

Book Value / Share (Annual)$8.45

Price vs S&P 500 (13W)-87.72%

Beta3.38x

Revenue / Share (TTM)$7.30

ROE (TTM)-53.31%

52-Week Low$1.40

vGradeB

gGradeF

mGradeF

vgmGradeD

CRIS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$5.21	-$4.02	+22.79%(+$1.19)
Q1 2026	May 12, 2026	-$5.80	-$25.00	-331.03%(-$19.20)
Q4 2025	Mar 24, 2026	-$8.65	-$9.95	-15.01%(-$1.30)
Q3 2025	Nov 6, 2025	-$12.00	-$9.80	+18.33%(+$2.20)
Q2 2025	Aug 5, 2025	-$30.30	-$13.60	+55.12%(+$16.70)

CRIS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRISCuris Inc	B	F	F	$1.49
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Curis Inc

Curis is a biotechnology company developing immuno-oncology and precision oncology therapies targeting solid tumors, diffuse large B-cell lymphoma, and hematological cancers. The company's pipeline includes five drug candidates: Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.